Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) Non Operating Income (2016 - 2025)

Cytokinetics (CYTK) has disclosed Non Operating Income for 16 consecutive years, with $11.9 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income changed N/A to $11.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $48.8 million through Dec 2025, changed N/A year-over-year, with the annual reading at $48.4 million for FY2025, 6.04% down from the prior year.
  • Non Operating Income for Q4 2025 was $11.9 million at Cytokinetics, up from $10.2 million in the prior quarter.
  • The five-year high for Non Operating Income was $17.1 million in Q3 2024, with the low at -$377000.0 in Q4 2021.
  • Average Non Operating Income over 5 years is $6.6 million, with a median of $6.8 million recorded in 2023.
  • The sharpest move saw Non Operating Income tumbled 117.57% in 2021, then surged 1693.94% in 2022.
  • Over 5 years, Non Operating Income stood at -$377000.0 in 2021, then soared by 1670.03% to $5.9 million in 2022, then increased by 28.16% to $7.6 million in 2023, then skyrocketed by 124.81% to $17.1 million in 2024, then tumbled by 30.22% to $11.9 million in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at $11.9 million, $10.2 million, and $13.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.